Clinical trials
Phase 2 Neoplasms trials in Australia
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
58 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2003 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 2 |
| 2007 | 3 |
| 2008 | 1 |
| 2009 | 1 |
| 2010 | 3 |
| 2011 | 1 |
| 2012 | 4 |
| 2013 | 1 |
| 2014 | 3 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 3 |
| 2019 | 5 |
| 2020 | 3 |
| 2021 | 5 |
| 2022 | 6 |
| 2023 | 1 |
| 2024 | 3 |
| 2025 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 24 |
| Terminated | 11 |
| Active, not recruiting | 10 |
| Recruiting | 8 |
| Unknown status | 3 |
| Withdrawn | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| AbbVie | 7 |
| Novartis Pharmaceuticals | 5 |
| GlaxoSmithKline | 4 |
| Eli Lilly and Company | 3 |
| Amgen | 2 |
| Bristol-Myers Squibb | 2 |
| Clovis Oncology, Inc. | 2 |
| Merck KGaA, Darmstadt, Germany | 2 |
| Merck Sharp & Dohme LLC | 2 |
| Peter MacCallum Cancer Centre, Australia | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Neoplasms | 58 |
| Neoplasm Metastasis | 11 |
| Melanoma | 8 |
| Carcinoma, Non-Small-Cell Lung | 7 |
| Breast Neoplasms | 6 |
| Multiple Myeloma | 5 |
| Recurrence | 5 |
| Hematologic Neoplasms | 4 |
| Leukemia | 4 |
| Pancreatic Neoplasms | 4 |
Trials
Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.